[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

60 Degrees Pharmaceuticals Inc WT (SXTPW)

60 Degrees Pharmaceuticals Inc WT (SXTPW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 1,410 K
  • Annual Income, $ -7,370 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/12/26
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0388 +1.29%
on 05/11/26
0.0518 -24.13%
on 05/13/26
-0.0067 (-14.57%)
since 04/28/26
3-Month
0.0380 +3.42%
on 03/09/26
0.1100 -64.27%
on 03/12/26
-0.0053 (-11.88%)
since 02/27/26
52-Week
0.0301 +30.56%
on 09/24/25
0.1560 -74.81%
on 08/12/25
-0.0221 (-35.99%)
since 05/27/25

Most Recent Stories

More News
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis

Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones Minimum enrollment to support interim analysis expected as soon as early July 2026 Randomized, double-blind,...

SXTP : 1.4900 (unch)
SXTPW : 0.0393 (-0.51%)
60 Degrees Pharmaceuticals Announces First Quarter 2026 Results

WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.  (NASDAQ:  SXTP ; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious...

SXTP : 1.4900 (unch)
SXTPW : 0.0393 (-0.51%)
60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website

Travelers can now purchase the only once-weekly, broad-spectrum malaria preventive online, through the Runway Health telehealth platform WASHINGTON, April 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees...

SXTP : 1.4900 (unch)
SXTPW : 0.0393 (-0.51%)
60 Degrees Pharmaceuticals Announces 2025 Annual Results

FY 2025 net product revenues increased 65% to $1,005,000 Current shelf capacity exhausted after raise of $4 million through an ATM facility WASHINGTON, March 31, 2026 (GLOBE NEWSWIRE) -- 60 Degrees...

SXTP : 1.4900 (unch)
SXTPW : 0.0393 (-0.51%)
60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

FDA has until May 25, 2026 to object to the notification, after which the Company will be free to market its proposed dietary supplement containing Australian Chestnut Extract Company has signed an option...

SXTP : 1.4900 (unch)
SXTPW : 0.0393 (-0.51%)
60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

All three patients enrolled in study have been cured, confirming high cure rate of  tafenoquine in immunosuppressed patients, as reported by Yale in a 2024 publication Company calls for existing babesiosis...

SXTP : 1.4900 (unch)
SXTPW : 0.0393 (-0.51%)
60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership

GoodRx to offer prescription savings of up to 30% for ARAKODA ® ( tafenoquine ) Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company’s marketing strategy Partnership...

GDRX : 2.92 (-1.68%)
SXTP : 1.4900 (unch)
SXTPW : 0.0393 (-0.51%)
60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use

WASHINGTON, Jan. 28, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.  (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing...

SXTP : 1.4900 (unch)
SXTPW : 0.0393 (-0.51%)
60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA® for Malaria Prevention

Partnership adds a travel-focused consumer telehealth platform to the ARAKODA ® marketing strategy, offering a new convenience to people planning travel to malaria-endemic regions of the world ARAKODA...

SXTP : 1.4900 (unch)
SXTPW : 0.0393 (-0.51%)
60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio

WASHINGTON, Jan. 15, 2026 (GLOBE NEWSWIRE) -- 60 Degree Pharmaceuticals, Inc. NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines...

SXTP : 1.4900 (unch)
SXTPW : 0.0393 (-0.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.